Health Canada endorsed important safety information on XGEVA (denosumab)

Subject: XGEVA® (denosumab) - Risk of severe symptomatic hypocalcemia, including fatal cases. Amgen Canada Inc., in consultation with Health Canada, would like to inform you of new important safety information related to hypocalcemia associated with XGEVA treatment. XGEVA is indicated in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumours for reducing the risk of developing skeletal-related events (SREs). XGEVA is not indicated in patients with multiple myeloma. Further information is here.